Key Highlights
- The FDA granted Vectus's request for a pre-IND Type B meeting on its proposed VB0004 development programme in idiopathic pulmonary fibrosis.
- Written FDA responses are expected by mid-November 2026 and will guide the next clinical and regulatory steps.
- Cash on hand was A$410,000 at 30 September 2026, down from A$719,000 at 30 June 2026.
- A A$450,000 Loan Facility from director Maurie Stang has been fully drawn.
Vectus Biosystems Limited (ASX:VBS) released its quarterly activities report and Appendix 4C on 29 October 2026, covering the quarter ended 30 September 2026. The clinical-stage biotechnology company reported that the FDA granted its request for a pre-Investigational New Drug Type B meeting on VB0004, its lead antifibrotic compound, and that it has appointed a US regulatory agent to prepare FDA submissions.
The FDA Pre-IND Process
Vectus said the FDA's written responses to its meeting package are expected by mid-November 2026. The company describes the interaction as formal guidance on its proposed programme in idiopathic pulmonary fibrosis, a progressive lung disease. After the request was granted, Vectus and its US regulatory agent began finalising the meeting package for submission.
The company has completed a Phase Ia clinical study of VB0004 in healthy volunteers, which it says established a favourable safety and pharmacokinetic profile. The pre-IND process is described as the basis for future clinical development in the United States.
US Regulatory Agent and Pipeline
Cardinal Health Regulatory Services was engaged in July 2026 as the US regulatory agent. The scope covers the Orphan Drug designation request, pre-IND communications and the IND application for VB0004 in IPF. The company says the appointment may also support other pipeline assets.
Beyond IPF, Vectus describes a pipeline of antifibrotic Assets targeting cardiovascular, renal and liver fibrosis. It says one renal fibrosis asset has been licensed to an international biotechnology company, which it presents as a pathway to milestone and Royalty revenue.
Cash Position and Funding
Net cash used in Operating Activities was A$309,000 for the quarter, and payments for patents, staff, clinical development and commercialisation totalled A$142,000. Vectus received an R&D cash refund of A$208,000 from the Australian Taxation Office in October 2026. Cash on hand was A$410,000 at quarter end, compared with A$719,000 at 30 June 2026.
The company's loan facility of up to A$450,000 with director Maurie Stang is fully drawn and can be repaid without penalty if alternative funding is secured. The report estimates about 1.33 quarters of funding available at the current operating outflow, and says the company is pursuing licensing opportunities and may dispose of some of its XORTX shares.
Sector Context and Risks to Watch
Antifibrotic drugs for IPF are developed in a field with a high level of regulatory scrutiny and long development timelines. Early FDA feedback shapes the design of later trials, but it does not guarantee approval of a clinical programme.
The main risks identified in the report are the short funding runway, the outcome of the FDA's written responses and the timing of licensing deals that the company says may provide upfront payments. Future quarterly reports will show whether these steps progress.
Final Word
Vectus has secured an FDA pre-IND meeting for VB0004 and a regulatory agent, but its cash runway is short and depends on licensing and other funding. The FDA's written responses and the company's funding decisions are the key points in its next report.






Please wait processing your request...